Clinical Insights on TLS Prophylaxis with Venetoclax in CCL

Mark Geyer, AYA Leukemia Program Leader at MSK Cancer Center, shared a post by Targeted Oncology on X, adding:

“Thrilled to work with superstar MSK fellow Yannis Valtis on this project, based on data from patients treated in our CLL program (led by Lindsey Roeker). Many of our patients choose 1st-line venetoclax-based time-limited therapy and these data help us understand their risks of TLS.

Lab TLS was uncommon and clinical TLS (in this cohort) not seen with the preventive and monitoring strategies used. Many can safely have venetoclax escalated outpatient. For colleagues outside of major centers, hopefully this increases comfort with outpatient venetoclax starts in appropriate patients.”

Quoting the post by Targeted Oncology:  .

“In the second part of the series, Mark Geyer and Yannis Valtis discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.”

Further information.
Source: Mark Geyer/X and Targeted Oncology/X